Skip to main navigation Skip to search Skip to main content

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

  • Filippo Pietrantonio
  • , F. Di Nicolantonio
  • , A. B. Schrock
  • , J. Lee
  • , F. Morano
  • , G. Fucà
  • , P. Nikolinakos
  • , A. Drilon
  • , J. F. Hechtman
  • , J. Christiansen
  • , K. Gowen
  • , G. M. Frampton
  • , P. Gasparini
  • , D. Rossini
  • , C. Gigliotti
  • , S. T. Kim
  • , M. Prisciandaro
  • , J. Hodgson
  • , A. Zaniboni
  • , V. K. Chiu
  • M. Milione, R. Patel, V. Miller, A. Bardelli, L. Novara, L. Wang, S. M. Pupa, G. Sozzi, J. Ross, M. Di Bartolomeo, A. Bertotti, S. Ali, L. Trusolino, A. Falcone, F. de Braud, C. Cremolini
  • IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
  • University of Milan
  • University of Turin
  • IRCCS Fondazione del Piemonte per l'Oncologia - Candiolo (TO)
  • Foundation Medicine, Inc.
  • Sungkyunkwan University
  • University Cancer and Blood Center
  • Memorial Sloan-Kettering Cancer Center
  • Ignyta, Inc.
  • University of Pisa
  • Fondazione Poliambulanza
  • University of New Mexico
  • St. Jude Children Research Hospital

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to comprehensively characterize the clinical, pathological and molecular landscape of RET rearranged metastatic colorectal cancer (mCRC). Patients and methods: In this case series, we compared clinical, pathological and molecular characteristics of 24 RET rearranged mCRC patients with those of a control group of 291 patients with RET negative tumors. RET rearranged and RET negative mCRCs were retrieved by systematic literature review and by taking advantage of three screening sources: (i) Ignyta's phase 1/1b study on RXDX-105 (NCT01877811), (ii) cohorts screened at two Italian and one South Korean Institutions and (iii) Foundation Medicine Inc. database. Next-generation sequencing data were analyzed for RET rearranged cases. Results: RET fusions were more frequent in older patients (median age of 66 versus 60 years, P=0.052), with ECOG PS 1-2 (90% versus 50%, P=0.02), right-sided (55% versus 32%, P=0.013), previously unresected primary tumors (58% versus 21%, P < 0.001), RAS and BRAF wild-type (100% versus 40%, P < 0.001) and MSI-high (48% versus 7%, P < 0.001). Notably, 11 (26%) out of 43 patients with right-sided, RAS and BRAF wild-type tumors harbored a RET rearrangement. At a median follow-up of 45.8 months, patients with RET fusion-positive tumors showed a significantly worse OS when compared with RET-negative ones (median OS 14.0 versus 38.0 months, HR: 4.59; 95% CI, 3.64-32.66; P < 0.001). In the multivariable model, RET rearrangements were still associated with shorter OS (HR: 2.97; 95% CI, 1.25-7.07; P=0.014), while primary tumor location, RAS and BRAF mutations and MSI status were not. Conclusions: Though very rare, RET rearrangements define a new subtype of mCRC that shows poor prognosis with conventional treatments and is therefore worth of a specific management.

Original languageEnglish
Pages (from-to)1394-1401
Number of pages8
JournalAnnals of Oncology
Volume29
Issue number6
DOIs
StatePublished - 1 Jun 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Colorectal cancer
  • Gene fusions
  • MSI-high
  • Prognosis
  • RET
  • Targeted therapy

Fingerprint

Dive into the research topics of 'RET fusions in a small subset of advanced colorectal cancers at risk of being neglected'. Together they form a unique fingerprint.

Cite this